Caplin Point Laboratories Limited announced that Dr. C K Gariyali has stepped down as an Independent Director of the Company, effective at the close of business on March 03, 2026. Her cessation is due to the completion of the maximum tenure permitted for an Independent Director role, as defined by the terms of her appointment. The company confirms that no other relationships require disclosure, providing clarity on the transition.
Cessation of Independent Directorship
Caplin Point Laboratories Limited has formally notified stock exchanges regarding a change in its Board composition. Dr. C K Gariyali (DIN: 08711546), who served as an Independent Director, ceased to hold office effective the close of business hours on March 03, 2026. This decision aligns with the company’s governance structure.
Reason for Departure
The reason cited for Dr. Gariyali’s departure is the completion of her second term as an Independent Director. This action adheres strictly to the maximum tenure limits stipulated for such positions, ensuring compliance with corporate governance guidelines. The cessation date is confirmed as March 03, 2026.
Regulatory Disclosure Confirmation
The detailed disclosure, mandated by SEBI Master circular dated January 30, 2026, confirms that there is Not Applicable disclosure regarding any relationships between directors. The filing was authenticated by Venkatram G, General Counsel & Company Secretary, on the day of the cessation.
Source: BSE
